The CIDC, housed at Dana-Farber Cancer Institute, serves the bioinformatics needs of the CIMAC-CIDC Network, including optimization of data collection methodologies suitable for immune-related biomarkers and data integration.

With the goal of developing a biomarker database for secondary use by the broader immuno-oncology community, CIDC is responsible for:

  • Creating data standards for all CIMAC assays
  • Creating and maintaining a centralized data repository and coordinated activities for CIMAC data submission to the CIDC
  • Developing and maintaining uniform bioinformatics pipelines for standardization of CIMAC data
  • Developing a shared infrastructure for executing integrative and correlative analysis on all CIMAC data
  • Developing data APIs and role-based access
  • Developing data visualization tools, enabling CIMAC investigators and external researchers to conduct their own analyses
  • Coordinating CIMAC-CIDC Network logistic and scientific activities for biomarker discovery and validation

Principal investigators

Photo of Shirley Liu, PhD

Shirley Liu, PhD

Director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute

Professor, Biostatistics and Computational Biology, Harvard T.H. Chan School of Public Health

Dr. Liu has extensive experience in bioinformatics algorithm development and data integration of cancer genomics, including methods to identify transcriptional regulators from chromatin dynamics or differentially expressed genes, identify regulators of drug response and resistance from CRISPR screens, estimate tumor infiltrating immune cells, infer immune repertoires from tumor bulk or single-cell RNA-seq data, and predict tumor response to targeted therapy and immunotherapy.

Photo of Ethan Cerami, PhD

Ethan Cerami, PhD

Director, Knowledge Systems Group and Principal Scientist, Department of Data Science, Dana-Farber Cancer Institute

Dr. Cerami's group focuses on building open-source bioinformatics platforms to enable cancer genomics discovery and precision cancer medicine. While at Memorial Sloan Kettering Cancer Center, he co-founded the cBioPortal for Cancer Genomics, one of the most widely used platforms for cancer genomics analysis and visualization. His group remains active in its continued development. He is also currently the Co-PI of the National Cancer Institute Human Tumor Atlas Network (HTAN) Data Coordinating Center (DCC), and the Co-PI of the DFCI MatchMiner platform for algorithmically matching patients to precision cancer medicine trials.